Evidence map›Paper›PMID 39458913›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study.

Felipe de Arriba de la Fuente, Mercedes Gironella Mesa, Miguel Teodoro Hernández García, Juan Alonso Soler Campos, Susana Herráez Rodríguez, María José Moreno Belmonte, Teresa Regueiro López, Miriam González-Pardo, María Casanova Espinosa, On Behalf Of The Carinae Study Investigators

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Felipe de Arriba de la FuenteHematology Department, Hospital Universitario Morales Meseguer, IMIB-Pascual Parrilla, Universidad de Murcia, 30008 Murcia, Spain.ORCID 0000-0002-4451-1318
Mercedes Gironella MesaHematology Department, Hospital Universitario Vall d'Hebrón, 08035 Barcelona, Spain.ORCID 0000-0002-8106-8909
Miguel Teodoro Hernández GarcíaHematology Department, Hospital Universitario de Canarias, 38320 La Laguna, Spain.
Juan Alonso Soler CamposHematology Department, Hosptial Universitario Parc Taulí, 08208 Barcelona, Spain.
Susana Herráez RodríguezHematology Department, Hospital Universitario Basurto, 48013 Bilbo, Spain.
María José Moreno BelmonteHematology Department, Hospital Universitario Virgen de la Arrixaca, 30120 Murcia, Spain.
Teresa Regueiro LópezSpanish Multiple Myeloma Patient Community (CEMMP), 24560 León, Spain.
Miriam González-PardoMedical Department, Janssen-Cilag S.A., Johnson & Johnson Company, 28042 Madrid, Spain.ORCID 0000-0003-4020-5038
María Casanova EspinosaDepartment of Hematology/Clinical Oncology, Hospital Costa del Sol, 29603 Marbella, Spain.
On Behalf Of The Carinae Study Investigators

Funding

Janssen-Cilag, S.A. Not applicable
6 · The paper itself

Abstract

Real-world evidence on the impact of monoclonal antibodies as first-line treatment in Spain is limited. This observational, retrospective and prospective, multicenter, descriptive study included 117 transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients divided into Group A, who received no daratumumab standard regimens, and the DVMP group (daratumumab, bortezomib, melphalan, and prednisone treatment). More than 90% of the patients in Group A received bortezomib, lenalidomide, or a combination of them. The median follow-up time for Group A was 38.2 months in comparison to 25.8 months for the DVMP group (

Indexed as

chemotherapydaratumumabimmunotherapymonoclonal antibodiesmultiple myeloma

Identifiers

PMID39458913
PMCPMC11510635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.